Drugs / MG01
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04891237 | Jun 2021 → Jan 2026 overdue | allergic asthma, allergic rhinitis | Inmunotek S.L. | Recruiting | No outcome recorded |
| Phase 3 | NCT04898283 | May 2021 → Oct 2026 expected | allergic asthma, allergic rhinitis | Inmunotek S.L. | Recruiting | No outcome recorded |
| Phase 3 | NCT04874714 | Apr 2021 → Oct 2023 | perennial allergic rhinitis | Inmunotek S.L. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04891237 ↗ |
| Modality | Protein / enzyme biologic | “Purified and polymerized with glutaraldehyde allergen extract” NCT04891237 ↗ |
| Route | Subcutaneous | “30,000 AU/mL of MM09 and 30,000 AU/mL of MG01 of subcutaneous immunotherapy” NCT04874714 ↗ |